Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA troubleshoots Artemis II toilet problem in otherwise smooth flight - 2Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- 3Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- 4White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
- 5The most effective method to Go Down Abundance through Ages with Disc Rates
- Chinese mega embassy could bring security advantages, says No 10
- Well known SUVs With Low Energy Utilization In 2024 vote
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- A definitive Manual for Internet Mastering and Expertise Improvement
- More charges filed against ex-left-wing RAF member Daniela Klette
- Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
